{"product_id":"omer-ansoff-analysis","title":"(OMER) Omeros Corporation ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Omeros Corporation Ansoff Matrix Analysis maps the company’s growth choices across market penetration, market development, product development, and diversification to guide strategy, investing, or planning. The page includes a real preview\/sample of the analysis so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOMIDRIA cataract-surgery share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOMIDRIA is Omeros Corporation’s only commercial product, and its penetration play is to win more use in the same cataract and intraocular lens replacement cases. U.S. cataract surgery volume tops 4 million cases a year, so even small share gains matter.\u003c\/p\u003e\n\u003cp\u003eThe levers are simple: surgeon familiarity, routine use in the workflow, and site-of-care access. If OMIDRIA is stocked and built into standard protocol, Omeros can lift use without needing a new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmbulatory surgery center adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation can deepen OMIDRIA use in ambulatory surgery centers, where most cataract cases are done; U.S. cataract surgery exceeds 4 million procedures a year. Penetration hinges on keeping OMIDRIA preferred against low-cost perioperative drops and irrigation mixes. In this core market, even small share gains can lift repeat use fast because ASC buyers favor products that simplify flow and support same-day discharge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital outpatient ophthalmology access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital outpatient departments are a current OMIDRIA channel, so Omeros Corporation can grow share by expanding purchasing and formulary access without changing the drug or its use. This is classic market penetration: more site coverage, more captured cataract cases, and no new indication needed. In FY2025, this kind of access-driven growth matters because OMIDRIA’s value depends on where it is stocked and used.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSurgeon repeat utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmeros Corporation can lift OMIDRIA repeat use by making it the default choice for the same ophthalmic surgeons already using it. That fits market penetration: more use in the existing cataract market, which sees about 4 million U.S. procedures a year. The play is habit, not new demand, so each returning surgeon can add more volume without changing the customer base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat use among current OMIDRIA surgeons\u003c\/li\u003e\n\u003cli\u003eTargets the existing cataract surgery pool\u003c\/li\u003e\n\u003cli\u003eSupports higher volume per surgeon\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement support for OMIDRIA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReimbursement support for OMIDRIA is a direct market-penetration move because cataract and other ophthalmic procedures depend on site-of-care economics. With more than 4 million cataract surgeries done in the U.S. each year, even a small gain in reimbursed use can lift share in Omeros Corporation’s current market. Omeros Corporation has a clear incentive to keep OMIDRIA available where the procedure is performed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore access can raise procedure-day use.\u003c\/li\u003e\n\u003cli\u003eReimbursement drives site-of-care adoption.\u003c\/li\u003e\n\u003cli\u003eU.S. cataract volume tops 4 million yearly.\u003c\/li\u003e\n\u003cli\u003eStronger coverage supports share gains.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOMIDRIA Targets Bigger Share of 4M+ U.S. Cataract Cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Omeros Corporation is OMIDRIA’s push to win more use in the same U.S. cataract surgery pool, where annual volume tops 4 million cases. The main levers are repeat surgeon use, ASC stocking, and broader hospital outpatient access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cataract cases\u003c\/td\u003e\n\u003ctd\u003e4M+ yearly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth lever\u003c\/td\u003e\n\u003ctd\u003eMore OMIDRIA use in current sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore channel\u003c\/td\u003e\n\u003ctd\u003eASCs and hospital outpatient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Omeros Corporation’s growth strategy through market penetration, market development, product development, and diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Omeros Ansoff Matrix snapshot to simplify growth planning and reduce strategic guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates authoritative Omeros sources to validate each Ansoff growth path, speeding due diligence and enabling traceable, defensible market and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarsoplimab in HSCT-TMA centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNarsoplimab has already cleared pivotal testing in HSCT-TMA, so the market development play is to move from Omeros Corporation’s ophthalmology roots into transplant centers and specialty hematology units. HSCT-TMA is rare but severe, with reported post-allogeneic transplant incidence around 10% to 35% and mortality often above 50%. That gives Omeros a focused, high-need niche with clear referral-pathway value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarsoplimab in IgAN nephrology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNarsoplimab is in Phase III for IgA nephropathy, a kidney disease that can account for 20% to 40% of primary glomerulonephritis cases in many regions. That gives Omeros Corporation a nephrology path outside its ophthalmology base, with kidney specialists and dialysis or transplant centers as the main buyers if data stay positive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarsoplimab in aHUS care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNarsoplimab’s Phase III aHUS program gives Omeros Corporation a second entry into the complement-mediated rare disease space, beyond its lead use in HSCT-TMA. The addressable base is narrow but high-value, centered on nephrologists and hematologists who already manage ultra-rare kidney and blood disorders. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNarsoplimab for COVID-19 inpatient use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmeros Corporation is extending narsoplimab from rare-disease use into a Phase II COVID-19 inpatient study, which is classic market development: the same drug is aimed at a new hospital infectious-disease setting.\u003c\/p\u003e\n\u003cp\u003eThis matters because hospitalized COVID-19 care is an acute-care market, so Omeros is trying to turn an existing asset into a broader revenue stream without starting from zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePhase II trial\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNew inpatient use\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExisting asset, new market\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOMS906 in PNH and alternative pathway disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOMS906, Omeros Corporation’s MASP-3 inhibitor, is in Phase I for paroxysmal nocturnal hemoglobinuria, a rare disease seen in about 10 to 20 people per million. That moves Omeros into hematology and complement-pathway disorders beyond its lead assets, with a larger addressable pool than ultra-niche programs. If it works, it could target PNH plus other alternative-pathway diseases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I in PNH\u003c\/li\u003e\n\u003cli\u003eExpands into hematology\u003c\/li\u003e\n\u003cli\u003eTargets complement-pathway disease\u003c\/li\u003e\n\u003cli\u003eBroader patient pool than lead assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmeros Targets High-Need Rare Disease Markets Beyond Ophthalmology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation’s market development centers on moving narsoplimab into new specialty care settings: HSCT-TMA transplant units, nephrology for IgA nephropathy, and hospital infectious-disease care for COVID-19. That is a shift from ophthalmology into high-need, rare-disease markets with tight referral paths and high unmet need.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNarsoplimab\u003c\/td\u003e\n\u003ctd\u003eHSCT-TMA\u003c\/td\u003e\n\u003ctd\u003e10% to 35% incidence; \u0026gt;50% mortality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNarsoplimab\u003c\/td\u003e\n\u003ctd\u003eIgA nephropathy\u003c\/td\u003e\n\u003ctd\u003e20% to 40% of primary glomerulonephritis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMS906\u003c\/td\u003e\n\u003ctd\u003ePNH\u003c\/td\u003e\n\u003ctd\u003e10 to 20 per million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eOmeros Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III narsoplimab for IgAN\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation is moving narsoplimab into Phase III for IgAN, adding a new labeled use to its complement-focused portfolio. IgAN is the most common primary glomerulonephritis, with incidence around 2 per 100,000 people a year, so this is clear product development. A successful readout could expand narsoplimab beyond its current late-stage pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III narsoplimab for aHUS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase III narsoplimab for aHUS gives Omeros Corporation a second rare-nephrology use for the same asset, so it is a direct product pipeline expansion within the complement franchise. aHUS is ultra-rare, at about 1 to 2 new cases per million people a year, so even small uptake can be meaningful while the market stays niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase II narsoplimab for COVID-19\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation’s Phase II narsoplimab COVID-19 study is a product development move: the same molecule is being tested in a new inpatient inflammatory use. That creates a second use case for the same asset, beyond its core program. In Ansoff terms, this is product development, not a new drug platform. It also keeps risk lower than building a brand-new molecule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOMS405 for opioid and nicotine dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOMS405 is Omeros Corporation’s Phase II PPAR program, moving the pipeline into CNS and addiction care. The U.S. overdose crisis is still huge, with 107,941 drug overdose deaths in 2022, so opioid dependence remains a large unmet need.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase II CNS\/addiction asset\u003c\/li\u003e\n\u003cli\u003eTargets opioid and nicotine dependence\u003c\/li\u003e\n\u003cli\u003eAdds pipeline breadth beyond core assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Ansoff, this is product development: a new therapy for an existing high-need market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOMS527 for addiction and compulsive disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOMS527 is a PDE7 inhibitor in Phase I, adding a new therapy class to Omeros Corporation’s CNS pipeline for addiction, compulsive disorders, and movement disorders. In Ansoff terms, it is product development: a new product built for existing CNS-focused markets, which can widen the company’s addressable patient pool without changing its core therapeutic area.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I asset\u003c\/li\u003e\n\u003cli\u003ePDE7 inhibitor\u003c\/li\u003e\n\u003cli\u003eNew CNS product\u003c\/li\u003e\n\u003cli\u003eTargets addiction and compulsive disorders\u003c\/li\u003e\n\u003cli\u003eAlso covers movement disorders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmeros Expands Pipeline With High-Value New Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation’s product development is centered on extending narsoplimab into new uses, especially Phase III IgAN and aHUS. IgAN affects about 2 per 100,000 people a year, while aHUS is about 1 to 2 per million, so each new label can add value fast. OMS405 and OMS527 also widen the CNS pipeline into addiction and movement disorders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eNew use\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003enarsoplimab\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003ctd\u003eIgAN, aHUS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMS405\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003eAddiction\/CNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMS527\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eAddiction\/CNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPR174 inhibitor platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation’s GPR174 inhibitor platform is still preclinical, so it adds 0 approved products and no near-term revenue yet. Still, it pushes the Company Name into a new mechanism and new disease areas, especially immune and immuno-oncology uses. In Ansoff terms, that is clear diversification: new technology, new markets, and higher R\u0026amp;D risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR T-cell therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmeros is pushing into preclinical CAR T-cell therapy programs, a clear diversification away from small-molecule and antibody assets. The move targets oncology, where the U.S. now has 7 approved CAR T therapies, showing real clinical and commercial demand. If Omeros advances even one candidate, it could tap a high-value market far beyond its current portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdoptive T-cell therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation's preclinical adoptive T-cell therapy work adds a second advanced-therapy path beyond its core pipeline, so it broadens the Ansoff move into diversification. It also opens exposure to cellular oncology, a separate market from antibody or small-molecule drugs. Because the program is still preclinical, it adds option value with limited near-term revenue, but it can expand the platform if data improve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGPCR discovery beyond rare disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmeros Corporation is broadening GPCR work beyond rare disease into metabolic, CNS, cardiovascular, and musculoskeletal targets, so this is clear diversification into noncore markets. As of 2026, that matters because these indications are much larger than the rare-disease pool, but they also need more capital and longer development timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves from niche to broader therapeutic markets\u003c\/li\u003e\n\u003cli\u003eSpreads pipeline risk across 4 disease areas\u003c\/li\u003e\n\u003cli\u003eRaises upside, but slows cash returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMASP-2 inhibitors for age-related macular degeneration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmeros Corporation is extending its complement franchise with preclinical small-molecule MASP-2 inhibitors for age-related macular degeneration, a move that pairs a new molecule class with a new eye-disease market. AMD affects about 196 million people worldwide, with cases projected to reach 288 million by 2040, so the target pool is far larger than Omeros Corporation’s rare-disease base. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew product: small-molecule MASP-2 inhibitor\u003c\/li\u003e\n\u003cli\u003eNew market: age-related macular degeneration\u003c\/li\u003e\n\u003cli\u003eStrategy: diversification\u003c\/li\u003e\n\u003cli\u003eImpact: widens complement reach beyond rare disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmeros’ Preclinical Pipeline Targets Bigger Markets—But Revenue Is Still Zero\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOmeros Corporation’s diversification is still preclinical, but it is moving into new drug classes and new markets: GPR174, CAR T-cell therapy, and MASP-2 for age-related macular degeneration. That lifts option value, but near-term revenue stays at 0 because none of these programs is approved. In 2026, AMD alone affects about 196 million people worldwide, showing why the upside is bigger than Omeros Corporation’s rare-disease base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2026 relevance\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPR174\u003c\/td\u003e\n\u003ctd\u003eNew immune targets\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAR T\u003c\/td\u003e\n\u003ctd\u003eNew oncology market\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMASP-2\u003c\/td\u003e\n\u003ctd\u003eAMD, 196M patients\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234794086665,"sku":"omer-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/omer-ansoff-matrix.webp?v=1785727468","url":"https:\/\/dcfanalyst.com\/products\/omer-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}